Edwards Lifesciences Corp
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -0.1% | +4.0% | +3.7% | +28.4% | +0.6% | -0.3% | +3.6% | -1.6% | +3.2% | -2.7% | +4.1% | |
| – | -0.8% | +3.3% | +8.3% | +49.0% | -6.6% | -1.2% | +5.9% | -3.3% | +6.0% | -7.6% | +9.5% | |
| – | -19.7% | +8.2% | +34.3% | +123.6% | -17.2% | +3.1% | +4.2% | -17.9% | +9.4% | -16.7% | +18.8% | |
| – | -12.4% | +4.0% | +17.2% | +123.4% | -10.6% | -1.9% | +4.2% | -5.4% | +10.0% | -13.1% | +15.8% | |
| – | +3.2% | +5.9% | -4.8% | -2.7% | -10.4% | +3.4% | +20.0% | -1.1% | +2.2% | +6.7% | -1.8% | |
| – | -12.5% | +33.6% | -15.1% | +7.8% | -1.6% | +2.5% | +2.5% | -0.1% | -1.3% | -0.6% | +1.1% | |
| – | – | – | – | – | +0.2% | +0.6% | +1.7% | +0.8% | +4.1% | – | – | |
| – | -11.7% | +9.4% | -8.1% | +39.5% | +10.7% | +0.1% | -0.1% | -0.5% | +0.0% | +2.9% | +7.2% | |
| – | -7.1% | +11.9% | -6.6% | +129.2% | +23.1% | -0.1% | -0.2% | -3.6% | -0.2% | +8.8% | +12.6% | |
| – | +0.0% | -3.6% | +1.8% | +29.5% | -10.9% | -5.4% | +1.8% | +6.4% | +9.5% | -10.9% | +5.0% | |
| – | -3.5% | -7.1% | +9.6% | +59.7% | -22.6% | -7.3% | +0.7% | +13.0% | +14.2% | -22.3% | +7.0% | |
| – | -5.8% | +8.3% | -13.3% | +12.6% | -3.3% | +1.3% | +9.3% | +3.5% | -8.6% | -0.8% | -0.8% | |
| – | -2.1% | +13.8% | -12.4% | -7.0% | +14.2% | -12.7% | -6.0% | +1.8% | +37.9% | -20.4% | +16.2% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -0.1% | +7.0% | +4.5% | +28.3% | +4.7% | +1.3% | +4.1% | -3.2% | +1.3% | -0.1% | +2.8% | |
| – | +4.3% | +3.9% | +3.9% | +31.6% | +3.0% | +2.7% | +2.5% | +2.1% | +0.6% | +2.7% | +1.7% | |
| – | -0.4% | -0.5% | +0.0% | -1.0% | -1.3% | -0.5% | +0.0% | -0.4% | -0.7% | -0.2% | -0.5% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.